A Multicenter Study of Cancer Incidence in CHEK2 1100delC Mutation Carriers

The CHEK2 1100delC protein-truncating mutation has a carrier frequency of ∼0.7% in Northern and Western European populations and confers an ∼2-fold increased risk of breast cancer. It has also been suggested to increase risks of colorectal and prostate cancer, but its involvement with these or other types of cancer has not been confirmed. The incidence of cancer other than breast cancer in 11,116 individuals from 734 non-BRCA1/2 breast cancer families from the United Kingdom, Germany, Netherlands, and the United States was compared with that predicted by population rates. Relative risks (RR) to carriers and noncarriers were estimated by maximum likelihood, via the expectation-maximization algorithm to allow for unknown genotypes. Sixty-seven families contained at least one tested CHEK2 1100delC mutation carrier. There was evidence of underreporting of cancers in male relatives (422 cancers observed, 860 expected) but not in females (322 observed, 335 expected); hence, we focused on cancer risks in female carriers. The risk of cancers other than breast cancer in female carriers was not significantly elevated, although a modest increase in risk could not be excluded (RR, 1.18; 95% confidence interval, 0.64-2.17). The carrier risk was not significantly raised for any individual cancer site, including colorectal cancer (RR, 1.60; 95% confidence interval, 0.54-4.71). However, between ages 20 to 50 years, the risks of colorectal and lung cancer were both higher in female carriers than noncarriers (P = 0.041 and 0.0001, respectively). There was no evidence of a higher prostate cancer risk in carriers than noncarriers (P = 0.26), although underreporting of male cancers limited our power to detect such a difference. Our results suggest that the risk of cancer associated with CHEK2 1100delC mutations is restricted to breast cancer, although we cannot rule out a small increase in overall cancer risk. (Cancer Epidemiol Biomarkers Prev 2006;15(12):2542–5)

[1]  A. Ashworth,et al.  Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study , 2005, The Lancet.

[2]  R. Hofstra,et al.  Colorectal cancer and the CHEK2 1100delC mutation , 2005, Genes, chromosomes & cancer.

[3]  J. Lubiński,et al.  CHEK2 is a multiorgan cancer susceptibility gene. , 2004, American journal of human genetics.

[4]  R. Eeles,et al.  Analysis of familial male breast cancer for germline mutations in CHEK2. , 2004, Cancer letters.

[5]  T. Rebbeck,et al.  Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers , 2004, Journal of Medical Genetics.

[6]  M. Goodman,et al.  Analysis of CHEK2 gene for ovarian cancer susceptibility. , 2004, Gynecologic oncology.

[7]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[8]  J. Lubiński,et al.  A novel founder CHEK2 mutation is associated with increased prostate cancer risk. , 2004, Cancer research.

[9]  J. Kładny,et al.  Rarity of germline 1100delC mutation in CHK2 in patients with malignant melanoma of the skin , 2004, Melanoma research.

[10]  M. Schutte,et al.  The CHEK2*1100delC mutation has no major contribution in oesophageal carcinogenesis , 2004, British Journal of Cancer.

[11]  E. Friedman,et al.  CHEK2*1100delC and male breast cancer risk in Israel , 2004, International journal of cancer.

[12]  A. Auvinen,et al.  CHEK2 1100delC is not a risk factor for male breast cancer population , 2004, International journal of cancer.

[13]  D. Easton,et al.  Role of CHEK2*1100delC in unselected series of non‐BRCA1/2 male breast cancers , 2004, International journal of cancer.

[14]  J. Ferlay,et al.  Cancer incidence in five continents. Volume VI , 2004, Cancer Causes & Control.

[15]  J. Schleutker,et al.  CHEK2 variants associate with hereditary prostate cancer , 2003, British Journal of Cancer.

[16]  L. Lipton,et al.  Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma. , 2003, Cancer letters.

[17]  L. Aaltonen,et al.  CHEK2 1100delC and colorectal cancer , 2003, Journal of medical genetics.

[18]  J. Klijn,et al.  The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. , 2003, American journal of human genetics.

[19]  P. Gregersen,et al.  Frequency of CHEK2*1100delC in New York breast cancer cases and controls , 2003, BMC Medical Genetics.

[20]  R. Eeles,et al.  Increasing evidence that germline mutations in CHEK2 do not cause Li‐Fraumeni syndrome , 2002, Human mutation.

[21]  O. Kallioniemi,et al.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. , 2002, American journal of human genetics.

[22]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[23]  J. Bartek,et al.  Chk2 kinase — a busy messenger , 2001, Nature Reviews Molecular Cell Biology.

[24]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[25]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[26]  Peter Devilee,et al.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.

[27]  Jacques Ferlay,et al.  Cancer incidence in five continents, Volume IX. , 1982 .

[28]  Brämer Gr.  International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[29]  K. Lange,et al.  Programs for pedigree analysis: Mendel, Fisher, and dGene , 1988, Genetic epidemiology.

[30]  G. Braemer.  International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[31]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.